The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2025

Filed:

Apr. 30, 2020
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Stephen Michael Burleigh, Seattle, WA (US);

Christopher Heath Nye, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70521 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4215 (2025.01); A61K 40/4224 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/7151 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/625 (2013.01); C12N 15/86 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01); A61K 2239/46 (2023.05); A61K 2239/48 (2023.05); C12N 2310/20 (2017.05); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01);
Abstract

Provided herein are engineered immune cells, e.g. T cells, expressing a chimeric receptor comprising an intracellular region comprising a CD3zeta (CD3ζ) signaling domain. In some embodiments, the engineered immune cells contain a modified CD247 locus that encodes the chimeric receptor or a portion thereof. In some embodiments, at least a portion of a CD3zeta chain encoded by CD247 genomic locus. Also provided are cell compositions containing the engineered immune cells, nucleic acids for engineering cells, and methods, kits and articles of manufacture for producing the engineered cells, such as by targeting a transgene encoding a portion of a chimeric receptor for integration into a region of a CD247 genomic locus. In some embodiments, the engineered cells, e.g. T cells, can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.


Find Patent Forward Citations

Loading…